Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-ranging trial

27% growth in prescriptions dispensed over prior quarter; 147% growth over comparable quarter in 2022. 5 consecutive quarters of double-digit growth. Click here to learn more ›